| Biomarker ID | 1569 |
| PMID | 31060542 |
| Year | 2019 |
| Biomarker | BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (CDK1): Signal transduction, Immune system, Signaling by GPCR, Interleukin-2 signaling pathway, Disease Pathways include (NCAPG): Aurora B signaling |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | MSKCC Cohort (GSE21032) was used in this dataset. 11 patients had low TMEFF2 expression, and 129 had high expression |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |